CN1509292A - 使用c-myc反义寡聚物治疗癌症的结合的方法 - Google Patents

使用c-myc反义寡聚物治疗癌症的结合的方法 Download PDF

Info

Publication number
CN1509292A
CN1509292A CNA028100719A CN02810071A CN1509292A CN 1509292 A CN1509292 A CN 1509292A CN A028100719 A CNA028100719 A CN A028100719A CN 02810071 A CN02810071 A CN 02810071A CN 1509292 A CN1509292 A CN 1509292A
Authority
CN
China
Prior art keywords
myc
antisense
oligomer
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028100719A
Other languages
English (en)
Chinese (zh)
Inventor
P��L������ɭ
P·L·艾弗森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sarepta Therapeutics Inc
Original Assignee
AVI Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AVI Biopharma Inc filed Critical AVI Biopharma Inc
Publication of CN1509292A publication Critical patent/CN1509292A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA028100719A 2001-05-17 2002-05-17 使用c-myc反义寡聚物治疗癌症的结合的方法 Pending CN1509292A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29172701P 2001-05-17 2001-05-17
US60/291,727 2001-05-17

Publications (1)

Publication Number Publication Date
CN1509292A true CN1509292A (zh) 2004-06-30

Family

ID=23121574

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028100719A Pending CN1509292A (zh) 2001-05-17 2002-05-17 使用c-myc反义寡聚物治疗癌症的结合的方法

Country Status (8)

Country Link
US (1) US20030087861A1 (enExample)
EP (1) EP1399462A4 (enExample)
JP (1) JP2004537517A (enExample)
KR (1) KR20040004629A (enExample)
CN (1) CN1509292A (enExample)
CA (1) CA2447052A1 (enExample)
NZ (1) NZ530101A (enExample)
WO (1) WO2002092617A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101624596B (zh) * 2009-08-12 2011-01-26 广州金琪基因技术研究发展中心 一种靶向c-myc癌基因的外指引序列
CN108338986A (zh) * 2017-01-23 2018-07-31 深圳开悦生命科技有限公司 一种用于治疗癌症的小分子rna及其应用

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7640582B2 (en) 2003-04-16 2009-12-29 Silicon Graphics International Clustered filesystem for mix of trusted and untrusted nodes
AU2004235396B2 (en) * 2003-04-29 2010-11-25 Sarepta Therapeutics, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US20060122140A1 (en) * 2004-11-22 2006-06-08 Wang Jui H In Vitro and in vivo silencing of human c-myc oncogene expression by poly-DNP-RNA
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
JP5122474B2 (ja) 2005-12-01 2013-01-16 プロネイ・セラピューティクス・インコーポレイテッド 両性リポソーム製剤
WO2007065017A2 (en) * 2005-12-01 2007-06-07 Pronai Therapeutics, Inc. Oligonucleotide cationic liposomal delivery system
US20090324587A1 (en) * 2005-12-01 2009-12-31 Neal Clifford Goodwin Cancer Therapies and Pharmaceutical Compositions Used Therein
US20070270371A1 (en) * 2006-03-31 2007-11-22 Brown Bob D Dosing and scheduling of oligomers
LT2735568T (lt) * 2006-05-10 2017-11-27 Sarepta Therapeutics, Inc. Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
CA2691673A1 (en) * 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
KR101981705B1 (ko) 2010-05-28 2019-05-24 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
KR20140097398A (ko) 2011-11-18 2014-08-06 사렙타 쎄러퓨틱스, 인코퍼레이티드 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트
ITMI20120275A1 (it) * 2012-02-24 2013-08-25 Biogenera Societa A Responsabilita Limitata Oligonucleotidi per la modulazione dell'espressione genica e loro usi
KR102192591B1 (ko) * 2013-09-09 2020-12-18 삼성전자주식회사 c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물
WO2016048054A2 (ko) * 2014-09-24 2016-03-31 삼성전자 주식회사 데이터 통신 보안을 위한 방법, 장치 및 시스템
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
NZ755416A (en) 2016-12-19 2023-05-26 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
WO2019217682A1 (en) 2018-05-09 2019-11-14 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
CA3107890A1 (en) * 2018-08-21 2020-02-27 Deep Genomics Incorporated Therapeutic splice-switching oligonucleotides
US20220088031A1 (en) * 2019-02-01 2022-03-24 Health Research, Inc. Methods and compositions for treating resistant and recurrent forms of cancer
KR20210134003A (ko) 2019-02-27 2021-11-08 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 안티센스 올리고머
US12338437B2 (en) 2020-05-11 2025-06-24 Stoke Therapeutics, Inc. OPA1 antisense oligomers for treatment of conditions and diseases
US12378267B2 (en) 2021-06-17 2025-08-05 Entrada Therapeutics, Inc. Synthesis of FMOC-protected morpholino monomers and oligomers
US20250289851A1 (en) 2022-04-22 2025-09-18 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics
CN121194802A (zh) * 2023-02-14 2025-12-23 斯托克制药公司 反义寡聚物调配物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515781A (en) * 1983-02-23 1985-05-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services 2',5'-Riboadenylate-morpholinoadenylate nucleotides
US6544755B1 (en) * 1992-08-26 2003-04-08 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of diseases by expression of the c-Myc gene
BR9405707A (pt) * 1993-01-07 1996-08-06 Univ Jefferson Inibiçao anti-sentido de c-myc para modular a proliferaçao de células de músculo liso
CA2250923A1 (en) * 1996-03-26 1997-10-02 Gabriella Zupi Oligonucleotide treatments and compositions for human melanoma
AU5752601A (en) * 2000-05-04 2001-11-12 Avi Biopharma Inc Splice-region antisense composition and method

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101624596B (zh) * 2009-08-12 2011-01-26 广州金琪基因技术研究发展中心 一种靶向c-myc癌基因的外指引序列
CN108338986A (zh) * 2017-01-23 2018-07-31 深圳开悦生命科技有限公司 一种用于治疗癌症的小分子rna及其应用

Also Published As

Publication number Publication date
NZ530101A (en) 2007-01-26
US20030087861A1 (en) 2003-05-08
KR20040004629A (ko) 2004-01-13
CA2447052A1 (en) 2002-11-21
EP1399462A4 (en) 2008-03-05
EP1399462A1 (en) 2004-03-24
JP2004537517A (ja) 2004-12-16
WO2002092617A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
CN1189562C (zh) 针对核糖核苷酸还原酶r1和r2组分的抗肿瘤反义序列
CN1918292A (zh) 用于调节bcl－2的寡聚化合物
EP2263679B1 (en) RNAi targeting cancer-related proteins
WO2002092617A1 (en) Combined approach to treatment of cancer using a c-myc antisense oligomer
CN1119830A (zh) 反义抑制C-myc以调节平滑肌细胞的增殖
EP1876893A2 (en) Cancer treatment by combined inhibition of proteasome and telomerase activities
JP2023013932A (ja) ＳＡＲＳ－ＣｏＶ－２ ＲＮＡ配列に基づく新規ｓｉＲＮＡ及びその利用
SK3652003A3 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
WO2019233922A1 (en) Oligonucleotides for modulating atxn2 expression
JP4424857B2 (ja) リボヌクレオチドレダクターゼのｒ１及びｒ２成分に対する抗腫瘍アンチセンス配列
CN101849007A (zh) 用于调节her3的rna拮抗剂化合物
CN1240439C (zh) 肿瘤基因开关药物
CN1871350A (zh) 用于引发肿瘤细胞致死的核酸
US20230073008A1 (en) Antisense nucleic acid that induces skipping of exon 50
EP1023313A1 (en) Inhibition of stress activated protein kinase (sapk) pathway and sensitization of cells to cancer therapies
KR101579638B1 (ko) 티미딜산 합성효소에 대한 ＲＮＡｉ 분자 및 그의 용도
JP2017506232A (ja) 腫瘍を治療するための阻害性オリゴヌクレオチド
KR102680316B1 (ko) 안티센스 올리고뉴클레오타이드
CN1948483B (zh) 抑制人RabJ基因表达的siRNA及其应用
KR20190087726A (ko) mTOR 유전자 및 STAT3 유전자의 발현을 동시에 억제하는 핵산
CN101076341A (zh) 酪蛋白激酶2反义疗法
KR20190009961A (ko) Bcl2 유전자 및 bi-1 유전자의 발현을 동시에 억제하는 핵산
KR101464360B1 (ko) 리보자임과 shRNA를 함유하는 아데노바이러스 및 이를 포함하는 암 치료용 조성물
CN1948482B (zh) 抑制人RabJ基因表达的反义寡核苷酸序列及其应用
EP4676546A2 (en) Compositions and methods for delivery of low dose effector agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication